Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatmentNaive patients: Results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial

Charles Williams Flexner, Camlin Tierney, Robert Gross, Adriana Andrade, Christina Lalama, Susan Eshleman, Judith Aberg, Ian Sanne, Teresa Parsons, Angela Kashuba, Susan L. Rosenkranz, Anne Kmack, Elaine Ferguson, Marjorie Dehlinger, Donna Mildvan

Research output: Contribution to journalArticle

Abstract

Background. Dosing frequency is an important determinant of regimen effectiveness. Methods. To compare efficacy of once-daily (QD) versus twice-daily (BID) antiretroviral therapy, we randomized human immunodeficiency virus (HIV)-positive, treatment-naive patients to lopinavir-ritonavir (LPV/r) administered at a dosage of 400 mg of lopinavir and 100 mg of ritonavir BID (n = 160) or 800 mg of lopinavir and 200 mg of ritonavir QD (n = 161), plus either emtricitabine 200 mg QD and extended-release stavudine at a dosage of 100 mg QD or tenofovir at a dosage of 300 mg QD. Randomization was stratified by screening HIV RNA level

Original languageEnglish (US)
Pages (from-to)1041-1052
Number of pages12
JournalClinical Infectious Diseases
Volume50
Issue number7
DOIs
StatePublished - Apr 1 2010

Fingerprint

Lopinavir
Ritonavir
Acquired Immunodeficiency Syndrome
Tenofovir
Randomized Controlled Trials
Clinical Trials
HIV
Stavudine
Random Allocation
Therapeutics
RNA

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatmentNaive patients : Results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. / Flexner, Charles Williams; Tierney, Camlin; Gross, Robert; Andrade, Adriana; Lalama, Christina; Eshleman, Susan; Aberg, Judith; Sanne, Ian; Parsons, Teresa; Kashuba, Angela; Rosenkranz, Susan L.; Kmack, Anne; Ferguson, Elaine; Dehlinger, Marjorie; Mildvan, Donna.

In: Clinical Infectious Diseases, Vol. 50, No. 7, 01.04.2010, p. 1041-1052.

Research output: Contribution to journalArticle

Flexner, CW, Tierney, C, Gross, R, Andrade, A, Lalama, C, Eshleman, S, Aberg, J, Sanne, I, Parsons, T, Kashuba, A, Rosenkranz, SL, Kmack, A, Ferguson, E, Dehlinger, M & Mildvan, D 2010, 'Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatmentNaive patients: Results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial', Clinical Infectious Diseases, vol. 50, no. 7, pp. 1041-1052. https://doi.org/10.1086/651118
Flexner, Charles Williams ; Tierney, Camlin ; Gross, Robert ; Andrade, Adriana ; Lalama, Christina ; Eshleman, Susan ; Aberg, Judith ; Sanne, Ian ; Parsons, Teresa ; Kashuba, Angela ; Rosenkranz, Susan L. ; Kmack, Anne ; Ferguson, Elaine ; Dehlinger, Marjorie ; Mildvan, Donna. / Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatmentNaive patients : Results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. In: Clinical Infectious Diseases. 2010 ; Vol. 50, No. 7. pp. 1041-1052.
@article{6db3863a46c344049b3ec4b21a5b535b,
title = "Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatmentNaive patients: Results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial",
abstract = "Background. Dosing frequency is an important determinant of regimen effectiveness. Methods. To compare efficacy of once-daily (QD) versus twice-daily (BID) antiretroviral therapy, we randomized human immunodeficiency virus (HIV)-positive, treatment-naive patients to lopinavir-ritonavir (LPV/r) administered at a dosage of 400 mg of lopinavir and 100 mg of ritonavir BID (n = 160) or 800 mg of lopinavir and 200 mg of ritonavir QD (n = 161), plus either emtricitabine 200 mg QD and extended-release stavudine at a dosage of 100 mg QD or tenofovir at a dosage of 300 mg QD. Randomization was stratified by screening HIV RNA level",
author = "Flexner, {Charles Williams} and Camlin Tierney and Robert Gross and Adriana Andrade and Christina Lalama and Susan Eshleman and Judith Aberg and Ian Sanne and Teresa Parsons and Angela Kashuba and Rosenkranz, {Susan L.} and Anne Kmack and Elaine Ferguson and Marjorie Dehlinger and Donna Mildvan",
year = "2010",
month = "4",
day = "1",
doi = "10.1086/651118",
language = "English (US)",
volume = "50",
pages = "1041--1052",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatmentNaive patients

T2 - Results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial

AU - Flexner, Charles Williams

AU - Tierney, Camlin

AU - Gross, Robert

AU - Andrade, Adriana

AU - Lalama, Christina

AU - Eshleman, Susan

AU - Aberg, Judith

AU - Sanne, Ian

AU - Parsons, Teresa

AU - Kashuba, Angela

AU - Rosenkranz, Susan L.

AU - Kmack, Anne

AU - Ferguson, Elaine

AU - Dehlinger, Marjorie

AU - Mildvan, Donna

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background. Dosing frequency is an important determinant of regimen effectiveness. Methods. To compare efficacy of once-daily (QD) versus twice-daily (BID) antiretroviral therapy, we randomized human immunodeficiency virus (HIV)-positive, treatment-naive patients to lopinavir-ritonavir (LPV/r) administered at a dosage of 400 mg of lopinavir and 100 mg of ritonavir BID (n = 160) or 800 mg of lopinavir and 200 mg of ritonavir QD (n = 161), plus either emtricitabine 200 mg QD and extended-release stavudine at a dosage of 100 mg QD or tenofovir at a dosage of 300 mg QD. Randomization was stratified by screening HIV RNA level

AB - Background. Dosing frequency is an important determinant of regimen effectiveness. Methods. To compare efficacy of once-daily (QD) versus twice-daily (BID) antiretroviral therapy, we randomized human immunodeficiency virus (HIV)-positive, treatment-naive patients to lopinavir-ritonavir (LPV/r) administered at a dosage of 400 mg of lopinavir and 100 mg of ritonavir BID (n = 160) or 800 mg of lopinavir and 200 mg of ritonavir QD (n = 161), plus either emtricitabine 200 mg QD and extended-release stavudine at a dosage of 100 mg QD or tenofovir at a dosage of 300 mg QD. Randomization was stratified by screening HIV RNA level

UR - http://www.scopus.com/inward/record.url?scp=77749329017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749329017&partnerID=8YFLogxK

U2 - 10.1086/651118

DO - 10.1086/651118

M3 - Article

C2 - 20192725

AN - SCOPUS:77749329017

VL - 50

SP - 1041

EP - 1052

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -